Fulgent Genetics (NASDAQ:FLGT) Issues FY 2025 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of -0.650--0.65 for the period, compared to the consensus earnings per share estimate of -0.660. The company issued revenue guidance of $310.0 million-$310.0 million, compared to the consensus revenue estimate of $310.4 million.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on FLGT shares. Raymond James restated an "outperform" rating and issued a $25.00 target price (up from $24.00) on shares of Fulgent Genetics in a research report on Monday. StockNews.com raised shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a report on Wednesday, March 5th. Finally, Piper Sandler reissued a "neutral" rating and set a $23.00 price target (up from $16.00) on shares of Fulgent Genetics in a research note on Tuesday.

Fulgent Genetics Stock Performance

Shares of NASDAQ:FLGT traded down $0.21 during trading on Wednesday, reaching $18.62. The stock had a trading volume of 127,885 shares, compared to its average volume of 267,861. The firm's fifty day moving average is $17.59 and its 200 day moving average is $18.07. Fulgent Genetics has a 52 week low of $14.57 and a 52 week high of $25.11. The stock has a market cap of $574.57 million, a price-to-earnings ratio of -3.38 and a beta of 1.00.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last issued its earnings results on Friday, May 2nd. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.22. Fulgent Genetics had a negative net margin of 59.39% and a negative return on equity of 1.81%. The business had revenue of $73.46 million for the quarter, compared to analyst estimates of $71.26 million. During the same period in the prior year, the firm earned ($0.01) earnings per share. Fulgent Genetics's revenue was up 14.0% on a year-over-year basis. On average, research analysts forecast that Fulgent Genetics will post -0.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Fulgent Genetics news, CFO Paul Kim bought 100,000 shares of Fulgent Genetics stock in a transaction dated Wednesday, March 5th. The stock was bought at an average cost of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 348,282 shares in the company, valued at approximately $5,558,580.72. The trade was a 40.28 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 33.11% of the company's stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.